5
Oct
2023
Fulfilling the Promise of Sickle Cell Gene Therapy
Two gene therapies for sickle cell disease, CRISPR/Vertex’s exa-cel and Bluebird Bio’s lovo-cel, are being reviewed by the FDA and are likely to win US approval for sale by the end of the year. While it will take more time to fully establish long-term safety and efficacy of these therapies, they offer a glimmer of hope for a cure. This... Read More
16
Mar
2023
The Last Mile of Hepatitis C Treatment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2023
When Life-Saving Medicines Are Ammunition in a Trade War
In early January, I held a telemedicine visit with a patient who reported a positive at-home COVID test and mild shortness of breath. During the visit, I looked through her health conditions and medications and decided that it was appropriate to prescribe Paxlovid. Later that day, she received the prescription from her local pharmacy, free of charge. Afterwards, I called... Read More
15
Dec
2022
Prescribing Cancer Drugs Off-Label is Tricky. Transparency and Standards Are Needed
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Feb
2022
For China-made drugs, Sintilimab Was the Exception, Not the Rule
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.